19th Nov 2021 11:37
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Reports the enrolment and treatment of the first patient in its multicentre SCIB1 phase 2 clinical trial at the Churchill Hospital, Oxford University Hospitals Trust, UK. The study is designed to assess whether the addition of SCIB1 to pembrolizumab will result in an improvement in the tumour response rate, progression-free survival and overall survival in patients with advanced melanoma.
As a result of the pandemic, screening and recruitment into the study was paused due to the prioritisation of Covid-19 patients in UK hospitals.
Current stock price: 20.25 pence, up 1.3%
Year-to-date change: up 45%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Scancell Holdings